36 results
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
A Serious and Life-Threatening Disease pLGGs are chronic and For the majority of pLGG patients in the relapsed setting, there is no standard of care
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
12 Jun 24
Regulation FD Disclosure
8:07am
Type Of Brain Tumor In Children A Serious and Life-Threatening Disease pLGGs are chronic and For the majority of pLGG patients in the relapsed setting
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
30 May 24
Day One Announces Sale of Priority Review Voucher for $108 Million
8:35am
Type Of Brain Tumor In Children A Serious and Life-Threatening Disease pLGGs are chronic and For the majority of pLGG patients in the relapsed setting
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
are chronic and relentless, with patients suffering profound tumor and treatment-associated morbidity that can impact their life trajectory over
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
24 Apr 24
Regulation FD Disclosure
8:01am
having a BRAF alteration. Until now, there had been no medicines approved for patients with pLGG driven by BRAF fusions.
“pLGG is a chronic … the remaining 20 percent have a V600 mutation.
Pediatric low-grade gliomas can be chronic and relentless, with patients suffering profound side effects
8-K
EX-99.2
vjv53s9 9kt2
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
0j16fvtv
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
od0wp5bgyoim 9x
8 Jan 24
Regulation FD Disclosure
8:30am
8-K
EX-99.1
t85pbcef9i09m 8o3
8 Jan 24
Regulation FD Disclosure
8:30am
8-K
EX-99.2
5292m654letitu rib1m
17 Nov 23
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
7:07am
8-K
EX-99.2
zpoiy07e
6 Nov 23
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
2zo3h d0oa6nropv
30 Oct 23
Regulation FD Disclosure
8:12am
8-K
EX-99.1
30ucc26b18zjj6ycmj
11 Sep 23
Regulation FD Disclosure
8:35am
8-K
EX-99.2
uaiar
11 Sep 23
Regulation FD Disclosure
8:35am
8-K
EX-99.2
8wnshnb 4dzl
16 Aug 23
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
8:06am
8-K
EX-99.2
rmp7nfe ett
7 Aug 23
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.1
8f93f3s b6e1yk
12 Jun 23
Regulation FD Disclosure
8:07am
8-K
EX-99.1
8anw07b
5 Jun 23
Regulation FD Disclosure
6:08am
8-K
EX-99.2
02yc5 b0jf1375zhu62
1 May 23
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
9:01am